Keywords: S*BIO, JAK2 inhibitor, Orphan status, Europe

S*BIO's JAK2 inhibitor SB1518 granted orphan status by European Commission for myelofibrosis

Article | 19 October 2010

Print This

Privately-held Singapore-based S*BIO Pte says that the European Commission has granted orphan drug designation to SB1518, its potent and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in